Elsevier to Discuss ‘Big Data’ and Bioinformatics in R&D at Drug Discovery Summit, Geneva

Presentation held June 2, 11:30 am - 12:00 pm, will address the advantage of data-driven decision-making to improve R&D outcomes 

Amsterdam, June 2, 2014

Alexander van Boetzelaer, from Elsevier, a world-leading provider of scientific, technical and medical information products and services, will deliver a presentation on sources of 'Big Data' in R&D and the implementation of bioinformatics to improve R&D outcomes at the 15th Annual Drug Discovery Leaders' Summit in Geneva, 2-3 June, 2014.

More than 250 delegates representing global pharmaceutical, biotech companies and internationally renowned academic institutions are expected to attend the Drug Discovery Leaders’ Summit in Geneva. Alexander van Boetzelaer, Managing Director Corporate Markets, will explore the impact of ‘Big Data’ utilization in research and development.

“This summit provides the opportunity to discuss how to extract and use meaningful data to improve R&D decision making – a significant challenge that faces many life science organizations as they grapple with the ‘Big Data’ challenge,” said Alexander van Boetzelaer, Elsevier’s Managing Director Corporate Markets. “We value this time with researchers and other colleagues across the industry, because we’re able to listen, gather feedback and ultimately improve our solutions and lead the way in advancing science, technology and health.”

Alexander van Boetzelaer will address:

Elsevier Life Science Solutions enables scientists from diverse disciplines to accelerate R&D through a bioinformatics portfolio that supports key workflows in chemistry, biology and medicine to better inform research decisions and improve research outcomes. The portfolio includes Embase, Pathway Studio, PharmaPendium, ScienceDirect, Scopus, TargetInsights, Reaxys, Reaxys Medicinal Chemistry and QUOSA.

The Drug Discovery Leaders’ Summit brings together senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve drug discovery. It features 55 presentations and case studies focused on the key issues in drug discovery and medicinal chemistry over two days.

To learn more about the Elsevier Life Science Solutions portfolio visit: http://www.elsevier.com/online-tools/life-science-solutions.

For more details about the 15th Drug Discovery Leaders’ Summit visit: http://www.drugdiscovery-summit1.com/. Elsevier representatives will also be available to speak with attendees at the Exhibition Room in the Grand Ballroom. 

---

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Amy Burnis
Director, Strategic Communications
Elsevier
+1 617 803 8344
a.burnis@elsevier.com